RIGL Stock Risk & Deep Value Analysis
Rigel Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About RIGL Stock
We analyzed Rigel Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RIGL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
RIGL Risk Analysis & Red Flags
What Could Go Wrong
The company's significant cash burn and high debt levels, as noted in previous analysis, could necessitate further dilutive equity raises if REZLIDHIA commercialization falters or regulatory approval is delayed. This would severely impact shareholder value and delay any path to profitability.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Lack of current financial data (earnings, cash flow, balance sheet) in real-time intelligence for a small-cap biotech.
- ⚠
Proposals to add shares to equity incentive plans for future potential dilution.
- ⚠
Vanguard's realignment to 0% direct holdings, despite being for internal reasons, could be perceived negatively by some investors.
Upcoming Risk Events
- 📅
Failure to secure REZLIDHIA regulatory approval
- 📅
Slower-than-expected commercial uptake of REZLIDHIA
- 📅
Need for additional dilutive capital raises
When to Reconsider
- 🚪
Failure to achieve REZLIDHIA approval by Q4 2026 (absent of new regulatory timeline).
- 🚪
Evidence of accelerating cash burn without corresponding revenue growth.
- 🚪
Significant further share dilution (e.g., >10% in a single quarter) without a clear, immediate path to positive FCF.
Unlock RIGL Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Rigel Pharmaceuticals Inc (RIGL) Do?
Market Cap
$479.30M
Sector
Healthcare
Industry
Biotechnology
Employees
162
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Visit Rigel Pharmaceuticals Inc WebsiteInvestment Thesis
Rigel is a high-risk, high-reward biotechnology investment positioned for potential 10x growth if REZLIDHIA (fostamatinib) secures regulatory approval for wAIHA and achieves strong commercialization, significantly expanding its market opportunity and ultimately leading to positive cash flow and reduced debt. The current valuation does not fully reflect this potential.
Is RIGL Stock Undervalued?
Unlock the full AI analysis for RIGL
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
RIGL Price Targets & Strategy
12-Month Target
$58.40
Bull Case
$85.00
Bear Case
$15.00
Valuation Basis
Based on successful regulatory approval of REZLIDHIA for wAIHA and initial commercial ramp-up, valuing the company at 2x current market cap of $0.54B (~$1.08B / 18.5M shares).
Entry Strategy
Consider dollar-cost averaging on any significant market weakness or a confirmed positive regulatory update for REZLIDHIA. No specific technical levels provided in research.
Exit Strategy
Take partial profits upon REZLIDHIA approval and early commercial success. Implement a stop-loss order if price drops significantly below cash burn threshold (e.g., $15.0).
Portfolio Allocation
5-10% for aggressive risk tolerance; not suitable for conservative portfolios due to high risk.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is RIGL Financially Healthy?
Valuation
P/E Ratio
1.62
Price/Book
1.44
Balance Sheet
Current Ratio
2.42
Quick Ratio
2.30
Debt/Equity
0.06
Other
Beta (Volatility)
1.10
Does RIGL Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
1 Identified
The moat's durability depends heavily on successful regulatory approvals and the ability to defend and extend patent exclusivity for its pipeline drugs. Competitive threats and clinical failures pose significant risks.
Moat Erosion Risks
- •Patent expiry or challenges from generic competitors.
- •Development of superior treatments by competitors.
- •Clinical trial failures or regulatory setbacks for pipeline assets.
RIGL Competitive Moat Analysis
Sign up to see competitive advantages
RIGL Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral
Institutional Sentiment
High institutional ownership (93.79%), but Vanguard's 0% holding post-realignment is a notable shift. No analyst consensus or recent upgrades/downgrades specified.
Insider Activity (Form 4)
No specific Form 4 filings identified for buys/sells in the last 90 days (from ~Jan 12, 2026).
Options Flow
Normal options activity (no specific data provided).
Earnings Intelligence
Next Earnings
2026-05-05
Surprise Probability
Medium
Historical Earnings Pattern
No consistent pattern identified (no historical data provided).
Key Metrics to Watch
Competitive Position
Top Competitor
Not provided in real-time intelligence.
Market Share Trend
Not provided in real-time intelligence.
Valuation vs Peers
Not provided in real-time intelligence. Difficult to assess without current financial metrics.
Competitive Advantages
- •Proprietary drug (TAVALISSE) for ITP.
- •Potential proprietary drug (REZLIDHIA) for wAIHA awaiting approval.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive RIGL Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (May 5, 2026)
- •REZLIDHIA (fostamatinib) regulatory approval for wAIHA (pending from previous analysis)
Medium-Term (6-18 months)
- •Initial commercialization and sales ramp-up of REZLIDHIA
- •Potential label expansion studies for TAVALISSE or REZLIDHIA
Long-Term (18+ months)
- •Expansion of pipeline beyond hematologic disorders and cancer
- •Potential strategic partnerships or M&A opportunities
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for RIGL?
- ✓
Clear and positive updates on REZLIDHIA regulatory pathway and approval.
- ✓
Demonstrated improvements in cash flow management and reduction in debt levels.
- ✓
Quarter-over-quarter growth in TAVALISSE sales and successful initial sales of REZLIDHIA.
Bull Case Analysis
See what could go right with Premium
Competing with RIGL
See how Rigel Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Rigel Pharmaceuticals Inc RIGL | $479.3M | 4.0 | 1.6 | — | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Rigel Pharmaceuticals Inc Makes Money
Rigel Pharmaceuticals Inc. is a biotechnology company that develops and commercializes innovative medicines, primarily for rare hematologic disorders and cancer. They generate revenue through the sales of their approved drug, TAVALISSE (fostamatinib), which is prescribed for adult patients with chronic immune thrombocytopenia (ITP). The company aims to expand its revenue base significantly through new drug approvals, such as REZLIDHIA for warm autoimmune hemolytic anemia (wAIHA), leveraging its scientific expertise to address unmet medical needs in specialized patient populations.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Rigel Pharmaceuticals Inc (RIGL)?
As of April 12, 2026, Rigel Pharmaceuticals Inc has a DVR Score of 4.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Rigel Pharmaceuticals Inc?
Rigel Pharmaceuticals Inc's market capitalization is approximately $479.3M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Rigel Pharmaceuticals Inc use?
RIGL is the ticker symbol for Rigel Pharmaceuticals Inc. The company trades on the NMS.
What is the risk level for RIGL stock?
Our analysis rates Rigel Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of RIGL?
Rigel Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of 1.6. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Rigel Pharmaceuticals Inc's revenue growing?
Rigel Pharmaceuticals Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is RIGL stock profitable?
Rigel Pharmaceuticals Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the RIGL DVR analysis updated?
Our AI-powered analysis of Rigel Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RIGL (Rigel Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.